We are proud to announce successful completion of Phase 1 trials for our novel anti-diabetic molecule, a GPR119 agonist, and are now progressing to Phase 2 trials. Additionally, we’ve applied for Phase 3 clinical trial approval for our breakthrough molecule targeting Non-Alcoholic Steatohepatitis (NASH). These advancements reflect our commitment to addressing complex global health challenges.

Our cutting-edge research includes two novel chemical entities (NCEs) in the preclinical stage, targeting autoimmune disorders and oncology. With these promising developments, we are opening new frontiers in personalized medicine and advanced healthcare solutions.

We have successfully developed two high-value complex generic APIs, including Sugammadex, alongside a confidential molecule. These innovations strengthen our position as a frontrunner in delivering high-quality, advanced therapies for better patient outcomes.

Mankind Pharma is at the forefront of developing biosimilars to address advanced cancer, allergy, and metabolic disease treatments. Leveraging platforms like mAbs and proteins, we aim to provide world-class solutions for life-threatening conditions.

Two of our US-ANDAs have been approved with CGT exclusivity:

1. Phenylephrine Hydrochloride Ophthalmic Solution USP, 2.5% (Approval Date: 29-Sep-2022)
2. Phenylephrine Hydrochloride Ophthalmic Solution USP, 10% (Approval Date: 11-Jan-2023)

These achievements mark another milestone in our journey to make advanced healthcare accessible globally.

Mankind Pharma leads the way in sustainability with patient-centric packaging innovations. Our preservative-free Lubimoist eye drops bottles and environmentally friendly labeling and leaflets ensure better care while minimizing environmental impact.